NUCRYST Pharmaceuticals Corp. Announces Management Realignment and R&D Portfolio Change; Discontinued Development of NPI 32101 for Inflammatory Bowel Disease (IBD)
WAKEFIELD, MA, April 30 /CNW/ - NUCRYST Pharmaceuticals, a developer and
manufacturer of medical products that fight infection and inflammation, today
announced that the Company has realigned its management team to further
advance its cost reduction and growth strategies. The realignment results in
increased management responsibilities for David C. McDowell, Vice President
Operations and the appointment of Edward Gaj, Jr., RPh to the newly created
position of Vice President Marketing.